Ton Berkien, economist by training, has a professional background in venture capital, corporate finance and pharma/biotech and is presently Chief Business Officer of Copenhagen based Nuevolution A/S, a main market NASDAQ listed company in Stockholm, Sweden. During his years at Nycomed and Takeda pharmaceutical, he was involved and leading several merger & acquisition processes, mainly in emerging markets like China, South America, former Eastern Europe, Turkey and Russia/CIS.
Sascha Bucher is currently the Head of Global Transactions at Roivant and the Site Head of Roivant Pharma Basel. Prior to joining Roivant, Sascha worked for Roche in numerous Business Development functions including in his role as Deputy Head of Global M&A where he was involved in 100+ transactions from deal initiation, diligence, deal structuring and negotiation lead where he closed over 35 global M&A and licensing deals. He has been a board member and BD advisor to Kyma Medical Technologies and is a member of the Baselaunch Initiative’s Selection Committee. Prior to Roche, Sascha was a banker at UBS. He holds an MBA in Finance and Economics from the University of Basel, and is a Harvard Business School GMP alumnus as well as a Certified European Financial Analyst and Asset Manager.
Dominique Doyen is Director Business Development at 4SC AG, Germany, a public biopharmaceutical company developing drugs in Oncology and joined the company in 2016. Dominique is leading Business Development, licensing and collaboration activities. Prior to 4SC, Dominique has worked in various Business Development and Sales roles in the pharmaceutical and cosmetic Industry, covering a wide range of drug development activities including clinical trials, manufacturing, product and technology licensing. Dominique holds an Engineer degree in Industrial Microbiology from Marseille University and an MBA from IAE- Graduate school of Management Aix-en-Provence.
Matthias joined Roche Diagnostics in 1993 and has held various positions in technology assessment, research and product development. In his current role as Chief Technology Officer, he leads a small team to assess platform technologies for future diagnostics products and provides input for business and strategy planning with insights on technology roadmaps. Previously, he has been responsible for new technology development and innovation within Roche Diabetes Care. Besides new technology platforms for next-generation test strips, continuous glucose sensors, miniaturized insulin pumps, all of which are currently in product development, he has piloted novel information management solutions for the management of T1 and T2 diabetes. His passion for data-driven solutions and business models originated during his time in the US Chief Technology Office (Pleasanton) around the year 2000, where he closely followed the emergence of internet businesses. Matthias holds a PhD in Medical Physics from University College London, U.K. and received his M.Sc. Degree in Physics from Ludwig Maximilians Universität in Munich, Germany. Besides his professional passion for business strategy and innovation management, he is very motivated to find better products and solutions for patients and improved outcomes
Stefan Fischer holds degree in engineering cybernetics from the University of Stuttgart and has received a PhD in pattern recognition from the Swiss Federal Institute of Technology in Lausanne. He was responsible for the development of intelligent cameras, video surveillance applications, robot arms and control system solutions. He is also a patent engineer and has consulted companies in patent valuation and innovation management. Since 2015 he is the National Contact Point (NCP) for SMEs, Energy and EURATOM at the Euresearch Network Office in Bern.
Marc is founder of BioVersys AG, a multi-award winning biopharmaceutical company focused on combatting antimicrobial resistance. Prior to BioVersys, he completed his studies in Biology at the University of Freiburg (Germany) and the University of Queensland (Australia). He holds a PhD in Biotechnology from the ETH Zurich. Marc gained additional business experience as Associate Intern at McKinsey & Company and insights to intellectual property rights at the patent offices Ernest T. Freylinger SA (Luxemburg) and Joachim Stuercken GmbH (Germany). Marc is winner of two Venture Leaders awards (2008 and 2016) and he is Vice President of the Board of the BEAM Alliance.
Thomas Hafen graduated in 1989 in International Affairs at the University of St. Gallen (HSG). He was awarded for his PhD thesis in political theory with the Prof. Walter Hug Price for “one of the best law thesis submitted in 1994/1995 at a Swiss University. He served the following ten years at the State Secretariat for Economic Affairs in different positions including Head of Division for Export and Investment Promotion. Thomas Hafen joined BÜHLMANN Laboratories in 2004, was appointed COO in 2006 and group CEO in July 2011. BÜHLMANN develops and manufactures in vitro diagnostics and operates in more than 70 countries. The BÜHLMANN Group includes affiliates in France, Italy, Austria, USA (North America) and Brazil, and direct sales to Germany.
Charles Hoare is an experienced healthcare investment banker, with more than 20 years in the sector. During that time he has executed a broad range of transactions including mergers, acquisitions, divestments, joint ventures and licensing transactions as well as raising capital (both equity and debt) in the public and private markets. He has also worked in multiple jurisdictions, with experience in the US, Europe, China, Japan, Russia, Brazil, India and Australia among other markets. Selected clients include Sanofi, GlaxoSmithKline, Boehringer Ingelheim, Eli Lilly, Pfizer, Nycomed and Galenica.
He currently leads the European healthcare M&A effort at Stifel, the growth focused US investment bank where he is building a team with focus on both M&A and capital raising in the US and Europe. In addition, until recently, he was a Non-Executive Director of Atlantic Healthcare Plc (the gastrointenstinal focused specialty pharmaceutical company), as well as serving on the boards of Laguna Ventures and Placehill Holdings. He also has a long-standing affiliation with the London School of Hygiene and Tropical Medicine, where he focuses on their third party commercialisation effort.
David is accountable for the innovation, strategy, operations, and related development deliverables for a broad portfolio of Anti-infectives programs including antibacterial and antiviral agents, as well as compounds targeting Neglected Tropical Diseases including Malaria. Earlier in his Novartis career, he was a Senior Director in the Healthcare Systems team, working with healthcare organizations around the world on partnership programs to improve patient outcomes and system productivity. Previously, David was a Government Medical Officer and acting Hospital Superintendent at Chitungwiza General Hospital, in the Ministry of Health, Zimbabwe. During this time he worked for nearly 3 years managing a pediatric ward and treating high acuity patients with commonly seen ailments such as pneumonia, diarrhea and malaria, often in the face of co-infection with HIV/AIDS. He was also a Family & Emergency Medicine physician in Canada. Prior to joining Novartis in February, 2011 he had extensive global pharmaceutical industry and business management experience during more than 10 years with Pfizer Inc. in New York & Hong Kong including roles in medical affairs, marketing, new product development and strategic planning. He also spent 4 years with the management consulting firm McKinsey & Company in New York & London working on a range of healthcare-related projects involving business development, global healthcare strategy, organizational change, hospital operations improvement, program evaluation and implementation. During this time, he supported the “Accelerating Access” initiative – a partnership between WHO, UNAIDS, World Bank, UNFPA, IFPMA and five Pharmaceutical Companies to increase availability of anti-retroviral drugs in Africa, with a pilot project in Uganda. David is a board-certified physician (University of Toronto; Canadian College of Family Physicians) with a Masters of Public Health in International Health from Johns Hopkins University.
Jochen holds a PhD in Bioinformatics and an Executive MBA. He has more than 17 years of experience in the Life Science and Diagnostics industry. In the last 10 years he has established the Innovation & IP Management department within Roche Diagnostics Centralised and Point of Care Solutions, the global market leader in in-vitro Diagnostics.
In the last 2 years Jochen has analyzed the global scene of accelerators and collaboration activities in the Digital Health space. At the beginning of 2018 he created the first Roche Digital Health Accelerator which is based in Munich, Germany. Besides his role as the project leader of the Accelerator Jochen also establishes new collaboration models to ensure value creation in the extended collaboration phase after the accelerator.
Allison has more than 25 years’ experience in the life sciences industry, predominantly within research and development. A physician by background, a recognised oncology specialist, with broad experience across other therapy areas, she has held a range of senior R&D roles, including those at BMS and Wyeth as well as being International Project Team Leader for many compounds in development, leading global Phase III programmes through to successful US and EU filings.
Allison worked as an independent consultant for many years with clients including: Genentech, J&J, Takeda Europe, Novartis, Roche, AZ, Sanofi, Lundbeck and Ipsen to name a few. She started as CMO for Avillion LLP leading the due diligence activities around the first deal Avillion delivered on for Pfizer and then stepped up to become CEO nearly five years ago.Allison has also recently been elected to Agenus’ Board of Directors.
Marie is a Life Sciences valuation expert and partner at Villiger Valuation. Based in Basel, she reviews 4-6bn of assets yearly from biotech companies in Europe and in the US. The expertise ranges from early stage project valuation, advanced modeling of funds to strategic support in licensing, trade sales and IPO situations. Regularly some of the biotech companies she supports are ranked in the top 10 largest european private financing rounds.
Aside Villiger Valuation, Marie also coordinates pro bono the BEAM Alliance (Biotech companies in Europe combating AntiMicrobial resistance), advocating the needs of 50 biotech companies at the forefront of innovation in AMR (AntiMicrobial Resistance) to repair their R&D, market and funding ecosystem.
Marie’s role is in the industry is to reconcile the "Value of Science" and the "Value of Cash" to increase velocity in innovation. She holds a Master in Finance and Strategy from Sciences Po Paris and has been graduated with merit from the Scube, a dual track made by Sciences Po and University Pierre et Marie Curie (Paris VI) in both Political & Fundamental Sciences. Her background spans from geeking Monte Carlo models to leading M&A transaction and coordinating political agenda for SMEs at European and UNO levels.
Jordi Sabé is a founding partner at Evolve HealthCare Partners, a PE firm that supports mainly European healthcare companies with growth acceleration needs or strategic repositioning (business transformation) needs, both organically or via M&A. Prior to founding Evolve HealthCare Partners, Jordi was Senior Vice President of Corporate Development at Almirall (2006-2018) and had global responsibilities on scouting, evaluation and execution of inorganic growth opportunities and strategic partnerships (External Innovation & M&A). Jordi was member of the Executive Committee, Pipeline Committee and Investment Committee at Almirall and reported to the CEO. As well, he was an executive member of the strategy Commission (Board of Directors). Jordi has more than 20 years of experience in Corporate Strategy and Development both from the financial advisory side (KPMG, Alta Partners) and the corporate side (GE Oil & Gas and, nowadays, ALMIRALL). Under Jordi’s leadership, Almirall has invested more than €2b in the last 12 years in different acquisitions of companies/products. In 2014, Almirall decided to change the strategic direction of the company and decided to divest to AZ its respiratory franchise for $2.1b and since then Almirall has repositioned itself as a leading dermatology player. More recently, in 2018, Almirall acquired Allergan’s medical dermatology business for $650m. Jordi holds a BA from the University of Barcelona and the University of California at Berkeley and holds an MBA from IE Business School / SDA Bocconi. During the last years Jordi has participated in different executive programs in Harvard, INSEAD and the University of Chicago.
Tim has more than 25 years experience in Life Sciences and Specialty Chemicals in different businesses and management positions at Ciba-Geigy/Novartis, Ciba Spec. Chemicals and Lonza. He joined LTS in 2013, as a Member of the Executive Board, responsible for Sales, Marketing and Business Development of LTS and its subsidiaries
Dr. Roberto Tracia is a partner with Oaklins Switzerland. In that role, he is advising corporate clients and family owned businesses in mergers, acquisitions, divestitures and other corporate finance related projects. He has been advising clients in the healthcare and other sectors for more than 20 years.
Dr. Tracia is Board Member of CAPSA, Camille Piquerez SA, and is member of the Corporate Finance Chapter of SECA, the Swiss Private Equity & Corporate Finance Association.
Dr. Tracia studied Business Administration at the Universities of St. Gallen, Luigi Bocconi in Milan as well as at Cornell University, NY, and earned his LL.M. at the University of Zurich.